PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$9.82
-0.26 (-2.58%)
▼
5d:
-24.54%
30d:
-28.69%
90d:
-42.17%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PHAR is down 24.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PHAR is down 24.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $9.82, which is considered oversold relative to its 30-day fair value range of $11.93 to $14.23. From a valuation perspective, the stock is trading at a discount (Forward PE: 181.8) compared to its historical average (215.7). Remarkably, the market is currently pricing in an annual earnings decline of 5.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHAR is in a strong downtrend. The price is currently testing key support at $9.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.35 (+249.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHAR is in a strong downtrend. The price is currently testing key support at $9.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.35 (+249.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.93 -
$14.23
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 249.8% below Wall St target ($34.35)
- WARNING: Recommendation downgraded due to -24.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$11.93 -
$14.23
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.62
Resistance Level
$13.40
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
181.85
Wall Street Target
$34.35
(+249.8%)
Revenue Growth (YoY)
-3.2%
Earnings Growth (YoY)
-62.9%
Profit Margin
2.5%
Valuation Discount vs History
-5.5% cheaper
PE vs Historical
181.9 vs 215.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.5%
(market-implied from PE analysis)
1-Year Target
$9.28
(-6%)
2-Year Target
$8.77
(-11%)
3-Year Target
$8.29
(-16%)
3-Yr Target (if PE normalizes)
(PE: 182→216)
$9.83
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 181.9, Growth: -76.6%)
$7.16
(+-27%)
Base:
(SPY PE: 20.7, Growth: -76.6%)
$0.82
(-92%)
Bear:
(PE: 17.6, Growth: -76.6%)
$0.69
(-93%)
📈
Valuation based on Current Earnings
Trailing PE: 72.00 | Current EPS (TTM): $0.14
Bull Case
$5.54
(-44%)
Analyst growth -50.0%, PE expands to 79.2
Base Case
$5.04
(-49%)
Market implied -50.0%, PE stable at 72.0
Bear Case
$6.85
(-30%)
Severe decline -20.0%, PE contracts to 61.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 181.9 to 215.7
Stabilization Target:
$11.65
(+18.6%)
PE Expansion Potential:
+18.6%
Share & Embed Analysis
Last updated: August 03, 2026 6:09 PM ET
Data refreshes hourly during market hours. Next update: 7:09 PM
Data refreshes hourly during market hours. Next update: 7:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
